References
- TurnerAMTamasiLSchleichFClinically relevant subgroups in COPD and asthmaEur Respir Rev20152413628329826028640
- BatemanEDHurdSSBarnesPJGlobal strategy for asthma management and prevention: GINA executive summaryEur Respir J200831114317818166595
- HanMKAgustiACalverleyPMChronic obstructive pulmonary disease phenotypes: the future of COPDAm J Respir Crit Care Med2010182559860420522794
- SuissaSDrazenJMMaking sense of triple inhaled therapy for COPDN Engl J Med2018378181723172429669218
- PostmaDSRabeKFThe asthma-COPD overlap syndromeN Engl J Med2015373131241124926398072
- PascoeSJWuWCollisonKANelsenLMWurstKELeeLAUse of clinical characteristics to predict spirometric classification of obstructive lung diseaseInt J Chron Obstruct Pulmon Dis20181388990229559773
- VogelmeierCFCrinerGJMartinezFJGlobal strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summaryEur Respir J2017493170021428182564
- HananiaNASharafkhanehACelliBAcute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trialRespir Res201112621219660
- VogelmeierCFCrinerGJMartinezFJGlobal strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summaryAm J Respir Crit Care Med2017195555758228128970
- van DijkWTanWLiPClinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohortAnn Fam Med2015131414825583891
- VestboJLangePCan GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease?Am J Respir Crit Care Med2002166332933212153965
- AaronSDTanWCBourbeauJDiagnostic instability and reversals of chronic obstructive pulmonary disease diagnosis in individuals with mild to moderate airflow obstructionAm J Respir Crit Care Med2017196330631428267373
- UlrikCSBackerVNonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthmaEur Respir J199914489289610573238
- MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
- PellegrinoRViegiGBrusascoVInterpretative strategies for lung function testsEur Respir J200526594896816264058
- HananiaNACelliBRDonohueJFMartinUJBronchodilator reversibility in COPDChest201114041055106321972384
- PrenticeHAManninoDMCaldwellGGBushHMSignificant bronchodilator responsiveness and “reversibility” in a population sampleCOPD20107532333020854046
- CalverleyPMBurgePSSpencerSAndersonJAJonesPWBronchodilator reversibility testing in chronic obstructive pulmonary diseaseThorax200358865966412885978
- QuanjerPHRuppelGLLanghammerABronchodilator response in FVC is larger and more relevant than in FEV1 in severe airflow obstructionChest201715151088109828040521
- CapaldiDPZhaNGuoFPulmonary imaging biomarkers of gas trapping and emphysema in COPD: (3)He MR imaging and CT parametric response mapsRadiology2016279259760826744928
- WoodruffPGBarrRGBleeckerEClinical significance of symptoms in smokers with preserved pulmonary functionN Engl J Med2016374191811182127168432
- HarveyBGStrulovici-BarelYKanerRJProgression to COPD in smokers with normal spirometry/low DLCO using different methods to determine normal levelsEur Respir J20164761888188927246083
- CouperDLavangeLMHanMDesign of the subpopulations and Intermediate outcomes in COPD study (SPIROMICS)Thorax2014695492495
- ReganEAHokansonJEMurphyJRGenetic epidemiology of COPD (COPDGene) study designCOPD201071324320214461
- DowLAsthma versus chronic obstructive pulmonary disease – exploring why “reversibility versus irreversibility” is no longer an appropriate approachClin Exp Allergy199929673974310336587